Monarch recruiting !

[Think2Succeed]

Two sites opened so far: 1 in Australia and 1 in New Zealand. From now on being a short must be very stressful....cohort 7 showed max KD after just 20 days from ARC-520 administration and let's not forget that Monarch is open label....

Link: clinicaltrials.gov/ct2/show/NCT02577029?spons=Arrowhead+Research+Corporation&lup_s=12%2F03%2F2015&lup_d=14&show_rss=Y&sel_rss=mod14

T2S

[labwd1]

Can't wait to see the data start rolling in.

[Think2Succeed]

Me too labwd1. Next week if my estimations are correct we should have news regarding final data of cohort 7. Then as soon as the first patient is dosed in Monarch we should hear again from the company (that's when they usually put out a press release and not when recruiting starts). Then we know that max KD is achieved in about 20-22 days from ARC-520 injection...probably when at least 5-6 patients are past max KD the company is going to inform us. If something exceptional happens (let's not forget that so far ARC-520 wasn't tested along PEG INF ) we could hear about that at any point. Bottom line is that once dosing starts it shouldn't take more than 2-3 months to have some Monarch data. Before that though we might hear about ARC-AAT.

T2S

[qbeing1010]

What might we expect to see in the final data from cohort 7?

[Think2Succeed]

qbeing1010,

Remember that in chimps initially we saw only 2 chimps showing signs of immune responses ? Then at DPARC 2015 that number rose to 7 out of 9. It would be fantastic news if this is replicated in humans as well.... Also we know that ARC-520 works much better in E+ chimps/patients and the chimps were all E- while cohort 7 are all E+ patients. The disadvantage though for this cohort 7 is that it was single dose (one 4 mg injection) while the chimps were all multi-dosed. But any signs of immune response in HUMANS after just one dose...can you imagine how big that would be ?

T2S

[Think2Succeed]

Monarch is now enrolling :

finance.yahoo.com/news/arrowhead-begins-dosing-phase-2b-123000935.html

Good timing with this press release given the state of the market and the motion to dismiss outcome. From now on it is very dangerous to be short in this stock...these are treatment naive patients and we're adding IFN too so anything is possible....the fact that is an open label study helps a lot too.

T2S